Trials
4 active
10 in total · 5 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Aficamten tablets, 5-20 mg daily, administered orally. Participants may continue on Aficamten until end of treatment criteria defined in the protocol is met.”In the company’s words, NCT04848506 on ClinicalTrials.gov
- Tested for
- Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy, Symptomatic Hypertrophic Cardiomyopathy (HCM), Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy
- Main trialPhase 3
- “This clinical trial will study the effects of aficamten (versus placebo) on the quality of life, exercise capacity, and clinical outcomes of patients with non-obstructive hypertrophic cardiomyopathy.”In the company’s words, NCT06081894 on ClinicalTrials.gov
- Other names
- CK-3773274
Other drugs for Symptomatic Hypertrophic Cardiomyopathy (HCM)
- SotagliflozinLexicon Pharmaceuticals · Phase 3
- HRS-1893Hengrui · Phase 3
- BHB-1893Braveheart Bio, Inc. · Phase 3
- BAY3723113Bayer · Phase 3
- NinerafaxstatImbria Pharmaceuticals, Inc. · Phase 2
- QG101-23-0Amckaus PTY LTD. · Phase 2
Coming up2
- Mar 2029Phase 2/3 trial completes · ClinicalTrials.gov
- Jan 2030Phase 2/3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 13 NovFDA approved a new use · Myqorzo
Trials10
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 31 Aug 2026 | A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) | |
| Phase 2/3Enrolling by invitation | Mar 2029 | Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM | |
| Phase 2/3Active, not recruiting | Jan 2030 | A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM). | |
| Phase 3Completed | 10 Nov 2023 | Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM | |
| Phase 3Completed | 28 Feb 2025 | Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM | |
| Phase 2Completed | 28 Feb 2023 | Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic Cardiomyopathy | |
| Phase 1Completed | 3 Jan 2020 | A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects | |
| Phase 1Completed | 5 Aug 2021 | Safety, Tolerability and Pharmacokinetics Study of CK-3773274 | |
| Phase 1Completed | 14 Nov 2023 | Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval | |
| Phase 2Authorised | not given | Learning From Early Aficamten In HCM (LEAF-HCM) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026